IBDEI1MT ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27301,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,27302,0)
 ;;=E11.21^^132^1312^17
 ;;^UTILITY(U,$J,358.3,27302,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27302,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,27302,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,27302,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,27303,0)
 ;;=E11.39^^132^1312^18
 ;;^UTILITY(U,$J,358.3,27303,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27303,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complication NEC
 ;;^UTILITY(U,$J,358.3,27303,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,27303,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,27304,0)
 ;;=E11.43^^132^1312^15
 ;;^UTILITY(U,$J,358.3,27304,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27304,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,27304,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,27304,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,27305,0)
 ;;=E11.59^^132^1312^13
 ;;^UTILITY(U,$J,358.3,27305,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27305,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Complications NEC
 ;;^UTILITY(U,$J,358.3,27305,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,27305,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,27306,0)
 ;;=E11.618^^132^1312^14
 ;;^UTILITY(U,$J,358.3,27306,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27306,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,27306,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,27306,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,27307,0)
 ;;=E11.621^^132^1312^16
 ;;^UTILITY(U,$J,358.3,27307,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27307,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,27307,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,27307,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,27308,0)
 ;;=E11.622^^132^1312^20
 ;;^UTILITY(U,$J,358.3,27308,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27308,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,27308,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,27308,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,27309,0)
 ;;=E11.65^^132^1312^19
 ;;^UTILITY(U,$J,358.3,27309,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27309,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,27309,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,27309,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,27310,0)
 ;;=E11.9^^132^1312^21
 ;;^UTILITY(U,$J,358.3,27310,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27310,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,27310,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,27310,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,27311,0)
 ;;=E13.9^^132^1312^22
 ;;^UTILITY(U,$J,358.3,27311,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27311,1,3,0)
 ;;=3^Diabetes Mellitus (Secondary) w/o Complications NEC
 ;;^UTILITY(U,$J,358.3,27311,1,4,0)
 ;;=4^E13.9
 ;;^UTILITY(U,$J,358.3,27311,2)
 ;;=^5002704
 ;;^UTILITY(U,$J,358.3,27312,0)
 ;;=E16.2^^132^1312^29
 ;;^UTILITY(U,$J,358.3,27312,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27312,1,3,0)
 ;;=3^Hypoglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,27312,1,4,0)
 ;;=4^E16.2
 ;;^UTILITY(U,$J,358.3,27312,2)
 ;;=^5002708
 ;;^UTILITY(U,$J,358.3,27313,0)
 ;;=E20.0^^132^1312^34
 ;;^UTILITY(U,$J,358.3,27313,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27313,1,3,0)
 ;;=3^Idiopathic Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,27313,1,4,0)
 ;;=4^E20.0
 ;;^UTILITY(U,$J,358.3,27313,2)
 ;;=^5002712
 ;;^UTILITY(U,$J,358.3,27314,0)
 ;;=E20.9^^132^1312^30
 ;;^UTILITY(U,$J,358.3,27314,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27314,1,3,0)
 ;;=3^Hypoparathyroidism,Unspec
